Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Oral CB-03-10 in Advanced Solid Tumors
NCT03863145Phase 1Recruiting
- Sponsor
- Cosmo Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- Jan 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CB-03-10 in solid tumor (advanced stage), sponsored by Cosmo Pharmaceuticals. Primary endpoints: Maximum Tolerated Dose at 29 days and Dose-Limiting Toxicity at 28 days. Started Jun 2022; status: recruiting.
02
Drugs
CB-03-10
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03863145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03863145.